Directly Administered Antiretroviral Therapy in Methadone Clinics Is Associated with Improved HIV Treatment Outcomes, Compared with Outcomes among Concurrent Comparison Groups
Open Access
- 1 June 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (11) , 1628-1635
- https://doi.org/10.1086/503905
Abstract
Background. Directly administered antiretroviral therapy (DAART) in methadone clinics has the potential to improve treatment outcomes for human immunodeficiency virus (HIV)—infected injection drug users (IDUs). Methods. DAART was provided at 3 urban methadone clinics. Eighty-two participants who were initiating or reinitiating highly active antiretroviral therapy (HAART) received supervised doses of therapy at the clinic on the mornings on which they received methadone. Treatment outcomes in the DAART group were compared with outcomes in 3 groups of concurrent comparison patients, who were drawn from the Johns Hopkins HIV Cohort. The concurrent comparison patients were taking HAART on a self-administered basis. The 3 groups of concurrent comparison patients were as follows: patients with a history of IDU who were receiving methadone at the time HAART was used (the IDU-methadone group; 75 patients), patients with a history of IDU who were not receiving methadone at the time that HAART was used (the IDU-nonmethadone group; 244 patients), and patients with no history of IDU (the non-IDU group; 490 patients). Results. At 12 months, 56% of DAART participants achieved an HIV type 1 RNA level P = .009), 33% of those in the IDU-nonmethadone group (P = .001), and 44% of those in the non-IDU group (P = .077). The DAART group experienced a median increase in the CD4 cell count of 74 cells/mm3, compared with 21 cells/mm3 in the IDU-methadone group (P = .04), 33 cells/mm3 in the IDU-nonmethadone group (P = .09), and 84 cells/mm3 in the non-IDU group (P = .98). After adjustment for other covariates in a logistic regression model, DAART participants were significantly more likely to achieve viral suppression than were patients in each of the 3 comparison groups. Conclusions. These results suggest that methadone clinic—based DAART has the potential to provide substantial clinical benefit for HIV-infected IDUs.Keywords
This publication has 23 references indexed in Scilit:
- Buprenorphine: Its Role in Preventing HIV Transmission and Improving the Care of HIV-Infected Patients with Opioid DependenceClinical Infectious Diseases, 2005
- Directly Administered Antiretroviral Therapy in an Urban Methadone Maintenance Clinic: A Nonrandomized Comparative StudyClinical Infectious Diseases, 2004
- Directly Observed Therapy for the Management of HIV-Infected Patients in a Methadone ProgramClinical Infectious Diseases, 2004
- Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program ReplicationClinical Infectious Diseases, 2004
- The Feasibility of a Community-Based Directly Administered Antiretroviral Therapy ProgramClinical Infectious Diseases, 2004
- Efficacy of Directly Observed Treatment of HIV Infection: Experience in AIDS Welfare HomesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Impact of Active Drug Use on Antiretroviral Therapy Adherence and Viral Suppression in HIV-infected Drug UsersJournal of General Internal Medicine, 2002
- Directly Observed Therapy for the Treatment of People with Human Immunodeficiency Virus Infection: A Work in ProgressClinical Infectious Diseases, 2002
- Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Providing medical care to methadone clinic patients: referral vs on-site care.American Journal of Public Health, 1994